Galapagos에 대한 매도 수량은 투자자에게 Galapagos의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Galapagos (NASDAQ:GLPG) 주식, 공매도 수량 보고

Galapagos

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Analyst Color

Biotech

News

Downgrades

Health Care

General

GILD

GLPG

뱅크 오브 아메리카 증권(BofA)은 유럽 제약회사 갈라파고스 NV(NASDAQ:GLPG)을 하향 조정하며, 단기적인 촉매제 부족에 대해 언급했다.갈라파고스의 기업 가치는 지속적으로 낮은 15억 ~ 20억 달러 사이에서 유지되고 있으며, 이에 대해 애널리스트들은 즉각적이거나 중기적인 해결책을 기대하지 않고 있다.게다가 이 회사의 주요 프로그램은 차별화가 불분명하고 성장을 촉진할 중요한 촉매제가 부족한 혼잡한 시장에 진출하고 있다.

느린 파이프라인 진전으로 어려운 싸움을 하는 갈라파고스 평가 하향: 분석가

Galapagos NV - American Depositary Shares

Galapagos NV

<ul>
<li>Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS</li>
<li>ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS)</li>
<li>Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements</li>
</ul>

ANNX

Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome

Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted the achievement of several clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE&#x2122;) platform as well as its glutamate modulation and ion channel programs.
Subcutaneously administered BHV-1300 achieved deep lowering of targeted IgG, with reductions &gt; 60% in the lowest subcutaneous dose tested in the ongoing multiple ascending dose (MAD) study. Subcutaneous BHV-1300 achieved progressive reduction in IgG within hours of each weekly dose administration in the MAD, and pharmacodynamic effects were sustained relative to baseline over the four-week study period. BHV-1300 has been safe and well-tolerated across the Phase 1 study. There were no clinically significant effects on albumin or liver function, and no increases in cholesterol were noted. Further enhancing the competitive safety profile and as intentionally designed, plasma IgG3 levels were preserved through the end of study week 4 to allow for healthy immune effector functioning. All AEs were mild, any drug-related AE resolved, and there were no discontinuations due to study drug related AEs. The optimized subcutaneous formulation in the MAD also showed substantially less inter-patient variability compared to previously reported intravenous BHV-1300. Escalating dose level cohorts of subcutaneous BHV-1300 are ongoing to explore the full range of IgG reductions possible with BHV-1300 for a wide range of future disease indications.&nbsp;

BHVN

Biohaven's BHV-1300 Achieves Advances in Targeted IgG Reduction Trials

FDA Approves Organon's Vtama (Tapinarof) For An Additional Indication Of The Topical Treatment Of Atopic Dermatitis In Adults And Pediatric Patients 2 Years Of Age And Older, Prior To Its Extended Target Action Date Of March 12, 2025

The company said the order, the largest in Vicon&#39;s 57-year history, underscores Vicon&#39;s commitment to delivering state-of-the-art surveillance solutions and is expected to be fulfilled in the Company&#39;s second fiscal quarter of 2025, fully within Cemtrex&#39;s fiscal year. Specific details about the customer remain confidential in accordance with non-disclosure agreements.

Contracts

CETX

Cemtrex Says Vicon Industries Subsidiary Received $10.4M Order For A State Government Corrections Facility In The Mid-Atlantic Region

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $40 price target.

Price Target

Reiteration

Analyst Ratings

BMEA

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target

Mizuho analyst Nitin Kumar maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Outperform and lowers the price target from $51 to $47.

Mizuho Maintains Outperform on Devon Energy, Lowers Price Target to $47

HC Wainwright &amp; Co. analyst Matthew Caufield initiates coverage on Zenas BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Buy rating and announces Price Target of $30.

Initiation

ZBIO

HC Wainwright & Co. Initiates Coverage On Zenas BioPharma with Buy Rating, Announces Price Target of $30

Mizuho analyst Nitin Kumar maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Outperform and raises the price target from $37 to $40.

CTRA

Mizuho Maintains Outperform on Coterra Energy, Raises Price Target to $40

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) with a Buy and maintains $20 price target.

CKPT

HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $20 Price Target

Mizuho analyst Nitin Kumar maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Neutral and lowers the price target from $137 to $134.

Mizuho Maintains Neutral on Exxon Mobil, Lowers Price Target to $134

FHTX

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Mizuho analyst Nitin Kumar maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Neutral and lowers the price target from $72 to $70.

Mizuho Maintains Neutral on Occidental Petroleum, Lowers Price Target to $70

HC Wainwright &amp; Co. analyst Mitchell Kapoor downgrades CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) from Buy to Neutral.

CARM

HC Wainwright & Co. Downgrades CARISMA Therapeutics to Neutral

Mizuho analyst Nitin Kumar maintains Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) with a Outperform and lowers the price target from $16 to $14.

TALO

Mizuho Maintains Outperform on Talos Energy, Lowers Price Target to $14

Mizuho analyst William Janela maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Outperform and lowers the price target from $50 to $45.

Mizuho Maintains Outperform on Murphy Oil, Lowers Price Target to $45

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Buy and maintains $49 price target.

BBIO

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $49 Price Target

The sales price represents an implied Enterprise Value/EBITDA multiple of 10.6x based on expected 2025 EBITDA. Proceeds from the sale will support the strategic priorities of Phillips 66, including returns to shareholders and debt reduction.The sale is expected to close in January 2025.

Asset Sales

Phillips 66 Agrees To Sell DCP GCX Pipeline LLC, Which Owns 25% Non-Operated Equity Interest In Gulf Coast Express Pipeline LLC, To Affiliate Of ArcLight Capital For Pre-tax Total Cash Proceeds Of $865M

Loop Capital analyst Alan Gould downgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Buy to Hold and raises the price target from $800 to $950.

NFLX

Loop Capital Downgrades Netflix to Hold, Raises Price Target to $950

Mizuho analyst William Janela maintains Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) with a Neutral and lowers the price target from $5 to $4.

Mizuho Maintains Neutral on Kosmos Energy, Lowers Price Target to $4

Ripple Labs CTO David Schwartz has issued a warning to investors about potential price volatility as Ripple's RLUSD <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42423570/ripple-secures-nydfs-approval-for-rlusd-stablecoin-xrp-price-up-9">stablecoin goes live</a>.
What Happened: "As RLUSD goes live, there may be supply shortages in the very early days before the market stabilizes," Schwartz <a href="https://x.com/JoelKatz/status/1868329931698245843">said</a> on Sunday on X.
He pointed out that while someone might pay significantly above $1 for a fraction of an RLUSD during the launch phase, such prices are unsustainable. 
"Rest assured, the price will come back to very close to $1 as soon as supply stabilizes. If it doesn't, something is very seriously wrong."
Schwartz also advised against speculative buying during the launch, stating, "Please don't FOMO into a stablecoin! This is not an opportunity to get rich." 
He said that the primary purpose of a stablecoin is price stability and that arbitrage mechanisms will quickly correct any short-term price distortions caused by early supply and demand imbalances.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42487721/bitcoin-much-better-than-gold-as-reserve-asset-says-crypto-hedge-fund-founder">Bitcoin &#8216;Much Better Than Gold&#8217; As Reserve Asset, Says Crypto Hedge Fund Founder</a>
Why It Matters: Ripple Lab secured regulatory approval for RLUSD from the New York Department of Financial Services (NYDFS) last week, marking a <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42423570/ripple-secures-nydfs-approval-for-rlusd-stablecoin-xrp-price-up-9">notable achievement for the company. </a>
The stablecoin, pegged to the US dollar, is designed to enhance Ripple's ecosystem and leverage the growing demand for stablecoins, which analysts predict could reach a $2 trillion market cap by 2028.
Ripple CEO Brad Garlinghouse announced the NYDFS approval earlier this week, confirming that RLUSD listings on exchanges and partner platforms are imminent. 
"When RLUSD is live, you'll hear it from Ripple first," Garlinghouse stated.
The stablecoin has already undergone rigorous testing on both the XRP Ledger and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) blockchain, ensuring its readiness for launch within the regulatory framework of New York's financial ecosystem.
Ripple&#8217;s native token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) is 122% over the last 30 days.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42486061/always-pay-the-tax-man-bitcoin-investor-sentenced-to-two-years-for-tax-evasion-on-crypto-gains">Always Pay The Tax Man: Bitcoin Investor Sentenced To Two Years For Tax Evasion On Crypto Gains</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$XRP

RLUSD Launch Is 'Not An Opportunity To Get Rich,' Ripple Executive Cautions

Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Galapagos (GLPG) to EUR 28 from EUR 30 and keeps a Hold rating on the s...

Galapagos price target lowered to EUR 28 from EUR 30 at Deutsche Bank

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haleon PLC Sponsored ADR (HLN – Research Report), Insmed (INSM – ...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)

Galapagos (GLPG) announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66th American Society of Hematology...

Galapagos to present data on CAR T-cell therapy candidates GLPG5101 and GLPG5201

Kepler Cheuvreux analyst Christophe Dombu downgraded Galapagos (GLPG) to Reduce from Hold with a price target of EUR 23.50, down from EUR 41. The c...

Galapagos downgraded to Reduce from Hold at Kepler Cheuvreux

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price target o...

Morgan Stanley Remains a Hold on Galapagos (GLPG)

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Galapagos (GLPG – Research Report) today and set a price target of $31.00. The com...

Galapagos (GLPG) Receives a Hold from Morgan Stanley

Galapagos (GLPG) has released an update. Galapagos has announced promising results from its Phase 1/2 study of the CD19 CAR T-cell therapy, GLPG510...

Galapagos Reports Promising CAR T-Cell Therapy Results

Leerink Partners analyst Faisal Khurshid has maintained their neutral stance on GLPG stock, giving a Hold rating on December 2. Faisal Khurshid's r...

Cautious Hold Rating for Galapagos: Unproven Efficacy and Logistical Concerns in CD19 CAR-T Programs

Kepler Capital analyst Christophe dombu maintained a Sell rating on Galapagos (0JXZ – Research Report) on December 9 and set a price target of €23....

Kepler Capital  Remains a Sell on Galapagos (0JXZ)

Galapagos Struggles To Carve A Path In A Crowded CAR-T Therapy Market

INSM

Press Releases

Galapagos receives transparency notification from FMR LLC

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Galapagos receives transparency notification from EcoR1 Capital

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Comments

Galapagos

매도 수량

Galapagos (NASDAQ:GLPG) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌